.png)
Executing the Strategic Plan
This week EyesOn Pharma is highlighting some recent business deals that are helping BioPharma firms execute their Strategic Plans. See more on Roche's manufacturing improvements, Earendil Labs' deal to further their antibody production, and Novo's cardiometabolic product line-extension deal.
Roche is continuing to execute their long-term strategy by improving manufactuing & pipeline options by building a $2 billion pharmaceutical manufacturing facility in Holly Springs, North Carolina.
Roche plans to invest $750 million to increase the size of its current production plant at the Genentech campus in Hillsboro, Oregon. The new investment will help build a fill-finish facility that will manufacture medication delivery devices, like auto-injectors and prefilled syringes, which essentially enable patients to take medications on their own at home.
Since it opened for business 20 years ago, the 75-acre facility in Portland’s western suburbs has been manufacturing therapies for neurology, immunology, and cancer.
According to the business, the new facility will offer end-to-end filling of both high-volume and low-volume pharmaceutical devices, offering Roche flexibility as its production requirements vary throughout its evolving portfolio. Roche plans to open the plant in 2031 and create 250 new, well-paying manufacturing jobs.
The company stated that Hillsboro is still essential to their U.S. operations because of its strong community and skilled staff. This expansion strengthens their dedication to U.S. manufacture and provides them with the flexibility to serve an expanding pipeline by adding end-to-end filing capabilities.
In 2015, Roche announced plans to invest $125 million in the Hillsboro facility’s expansion, which at the time was estimated to create up to 100 new employment opportunities. The expenditure was a component of a $800 million effort to improve Roche’s capacity to manufacture biologic medications in 2013. 500 jobs were created by the program in the United States, Germany, and Switzerland, the home nation of Roche.
In May 2025, Roche announced plans to construct a $700 million manufacturing plant in Holly Springs to carry out fill-finish for next-generation medications for metabolic disorders like obesity. The corporation then raised the stakes at the location in January of this year, announcing that it would invest a total of $2 billion in campus development.
In April of last year, Roche announced a $50 billion U.S. commitment, which includes the Holly Springs and Hillsboro projects. Roche is one of several major pharmaceutical companies that have attempted to circumvent the pharmaceutical tariffs imposed by the Trump administration by promising to invest in domestic manufacturing and research and development.
According to the firms, there are 13 production and 15 research and development facilities under the Roche and Genentech umbrella in the United States, with around 25,000 employees spread across 24 locations in eight states.
For more Details:
Earendil Labs is being paid $55 million up front by Roche’s Genentech to find and create several bispecific antibodies. The oncology-focused acquisition has milestones that could increase its worth above $1.5 billion.
Over the last 18 months, Earendil has gained popularity. In April 2025, Sanofi paid $125 million for two bispecifics, and in January, it committed an additional $160 million in cash and near-term milestones for more bispecifics. The total value of the transactions might reach milestones of over 44 billion. In the meantime, Earendil funded $787 million in March and signed a $885 million contract with WuXi WDC for antibody-drug conjugate (ADC) technology in February.
While Earendil was used by Sanofi to produce bispecific antibodies against autoimmune diseases, Genentech has looked to the well-funded startup for resources to fill its oncology pipeline. In oncology, Earendil will spearhead the search for antibodies and research on bispecifics against predetermined target combinations.
Before transferring the programs to Genentech for international clinical trials and commercialisation, the biotech will advance them through early clinical development. As the initiatives progress, Genentech will pay development, regulatory, and sales milestones in addition to tiered royalties on net product sales.
One week after Roche, Genentech’s parent firm, paid Dualitas Therapeutics $36.5 million to screen more than 300,000 new bispecific combinations, word of the deal leaked. Immunology and inflammatory illnesses were the main topics of Roche’s agreement.
The targets selected for their programs have not been made public by either Genentech or Earendil. However, Earendil emphasised the high-level justification for creating anticancer bispecifics, stating in a statement that it is particularly difficult for medicines targeting a single mechanism to have long-lasting benefit because tumour growth and metastasis depend on many interaction pathways.
Earendil applied its drug development platform to the modality since bispecifics allow a single molecule to treat complementary disease processes. Earendil has presented the AI-enabled platform as a means of creating antibody sequences on a large scale. The platform has capabilities for molecular optimisation and antibody property prediction.
Earendil has developed a comprehensive early-stage pipeline in oncology, inflammation, and immunology using the platform. Earendil’s cancer pipeline is dominated by ADCs, especially assets with bispecific targeting molecules. Additionally, the biotech is creating a number of T-cell engagers, the most sophisticated of which binds to two different, non-overlapping GUCY2C and DLL3 epitopes. Additionally, Earendil possesses a CEACAMxCDH17 bispecific.
For more Details
Novo is using BD to expand their CardioMetabolic pipeline. They haves reached a $1.33 billion agreement to merge Big Pharma’s obesity and Type 2 diabetes medications with Nanexa’s long-acting injectable drug delivery system.
Novo now has an exclusive worldwide license to use Nanexa’s technology with specific peptides for conditions like obesity, Type 2 diabetes, and other cardiometabolic disorders. PharmaShell, a technique developed by Nanexa, coats medication particles with an inorganic substance. At the injection site, coated particles create depots where drug particles enter the bloodstream as the coating dissolves.
Novo has determined that the technology is a good fit for its aims to expand the dosing windows of its medications in order to differentiate them. The Danish pharmaceutical company has been granted permission by Nanexa to use the PharmaShell platform in up to five programs. Monthly and quarterly administration frequencies are Novo’s goals.
Up to $700 million is the total value of the development and regulatory milestones as well as the upfront payment. Sales milestones are linked to the remaining $626 million. The amount of the advance payment has not been revealed by Novo or Nanexa. Nanexa received $3 million from Moderna last year in exchange for a potential $500 million partnership.
Days after Novo talked about its existing line of long-acting injectables, the deal was made public. The pharmaceutical company’s chief scientific officer outlined plans to introduce a once-monthly GLP-1 medication into the clinic this year during a Capital Markets Day speech, where Novo struggled to win over investors.
Since it cannot guarantee that the first will be the best, the business would declare that it genuinely expects to see at least three or four first human doses with once-monthly GLP-1 over the course of the following year. The business must take into account this half-life in its entirety. Others have given it half-lives, although they don’t always fit well with once-monthly therapy.
In February, Pfizer released results on its once-monthly GLP-1 medication candidate. In its $10 billion acquisition of Metsera, a biotech that Novo also attempted to purchase, the pharmaceutical company obtained the chemical. When questioned about Pfizer’s findings in June, the company stated that it was unsure if the data was as convincing as it had hoped for, especially when it came to tolerability and, to a lesser extent, efficacy. It must have a very appealing tolerability profile in order to be administered to patients once a month.
Long-acting compounds are another area of focus for GLP-1 leader Eli Lilly. Last year, the pharmaceutical company signed a $870 million contract to use Camurus’ technology. In June, Lilly expanded the agreement to encompass amylin receptor agonist.
For more Details:
